Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 18/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431657 | 0.84 | HCAR2 (0.57) | HCAR2SLC6A4 | |
| SCHEMBL21995952 | 0.84 | HCAR2 (0.57) | HCAR2SLC6A4 | |
| SCHEMBL4933770 | 0.83 | HCAR2 (0.44) | HCAR2SLC6A4CCNE2CCNE1CDK2 | |
| SCHEMBL24877924 | 0.79 | KDM4E (0.43) | HCAR2 | |
| SCHEMBL679590 | 0.79 | KDM4E (0.43) | HCAR2 | |
| SCHEMBL1433023 | 0.72 | CDK2 (0.50) | HCAR2CDK2 | |
| SCHEMBL21686207 | 0.72 | HCAR2 (0.31) | HCAR2 | |
| SCHEMBL14452806 | 0.64 | HCAR2 (0.76) | HCAR2 | |
| SCHEMBL3958134 | 0.63 | SLC6A3 (0.35) | — | |
| SCHEMBL17478495 | 0.62 | HCAR2 (0.66) | HCAR2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | HCAR2 2789/4885SLC6A4 4700/4885CCNE2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.